Munro N: Immunology and immunotherapy in critical care: An overview. AACN Adv Crit Care. 30:113–125. 2019.PubMed/NCBI View Article : Google Scholar

de Visser KE, Eichten A and Coussens LM: Paradoxical roles of the immune system during cancer development. Nat Rev Cancer. 6:24–37. 2006.PubMed/NCBI View Article : Google Scholar

Lin WW and Karin M: A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest. 117:1175–1183. 2007.PubMed/NCBI View Article : Google Scholar

Nishimura T, Iwakabe K, Sekimoto M, Ohmi Y, Yahata T, Nakui M, Sato T, Habu S, Tashiro H, Sato M and Ohta A: Distinct role of antigen-specific T helper type 1 (Th1) and Th2 cells in tumor eradication in vivo. J Exp Med. 190:617–627. 1999.PubMed/NCBI View Article : Google Scholar

DeNardo DG and Coussens LM: Inflammation and breast cancer. Balancing immune response: Crosstalk between adaptive and innate immune cells during breast cancer progression. Breast Cancer Res. 9(212)2007.PubMed/NCBI View Article : Google Scholar

Mailliard RB, Egawa S, Cai Q, Kalinska A, Bykovskaya SN, Lotze MT, Kapsenberg ML, Storkus WJ and Kalinski P: Complementary dendritic cell-activating function of CD8⁺ and CD4⁺ T cells: Helper role of CD8⁺ T cells in the development of T helper type 1 responses. J Exp Med. 195:473–483. 2002.PubMed/NCBI View Article : Google Scholar

Srivastava MK, Sinha P, Clements VK, Rodriguez P and Ostrand-Rosenberg S: Myeloid derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine. Cancer Res. 70:68–77. 2010.PubMed/NCBI View Article : Google Scholar

Gabrilovich DI, Ostrand-Rosenberg S and Bronte V: Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol. 12:253–268. 2012.PubMed/NCBI View Article : Google Scholar

Gabrilovich DI and Nagaraj S: Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 9:162–174. 2009.PubMed/NCBI View Article : Google Scholar

Mantovani A and Sica A: Macrophages, innate immunity and cancer: Balance, tolerance, and diversity. Curr Opin Immunol. 22:231–237. 2010.PubMed/NCBI View Article : Google Scholar

Solinas G, Germano G, Mantovani A and Allavena P: Tumorassociated macrophages (TAM) as major players of the cancerrelated inflammation. J Leukoc Biol. 86:1065–1073. 2009.PubMed/NCBI View Article : Google Scholar

Franklin RA, Liao W, Sarkar A, Kim MV, Bivona MR, Liu K, Pamer EG and Li MO: The cellular and molecular origin of tumor-associated macrophages. Science. 344:921–925. 2014.PubMed/NCBI View Article : Google Scholar

Nielsen SR and Schmid MC: Macrophages as key drivers of cancer progression and metastasis. Mediators Inflamm. 2017(9624760)2017.PubMed/NCBI View Article : Google Scholar

Buchbinder EI and Desai A: CTLA-4 and PD-1 pathways: Similarities, differences, and implications of their inhibition. Am J Clin Oncol. 39:98–106. 2016.PubMed/NCBI View Article : Google Scholar

Schreiber RD, Old LJ and Smyth MJ: Cancer immunoediting: Integrating immunity's roles in cancer suppression and promotion. Science. 331:1565–1570. 2011.PubMed/NCBI View Article : Google Scholar

Lesterhuis WJ, Haanen JB and Punt CJ: Cancer immunotherapy-revisited. Nat Rev Drug Discov. 10:591–600. 2011.PubMed/NCBI View Article : Google Scholar

Galluzzi L, Vacchelli E, Bravo-San Pedro JM, Buqué A, Senovilla L, Baracco EE, Bloy N, Castoldi F, Abastado JP, Agostinis P, et al: Classification of current anticancer immunotherapies. Oncotarget. 5:12472–12508. 2014.PubMed/NCBI View Article : Google Scholar

Cobaleda-Siles M, Henriksen-Lacey M, Ruiz de Angulo A, Bernecker A, Gómez Vallejo V, Szczupak B, Llop J, Pastor G, Plaza-Garcia S, Jauregui-Osoro M, et al: An iron oxide nanocarrier for dsRNA to target lymph nodes and strongly activate cells of the immune system. Small. 10:5054–5067. 2014.PubMed/NCBI View Article : Google Scholar

Khalil D, Smith E, Brentjens R and Wolchok JD: The future of cancer treatment: Immunomodulation, CARs and combination immunotherapy. Nat Rev Clin Oncol. 13:273–290. 2016.PubMed/NCBI View Article : Google Scholar

Michielin O, van Akkooi ACJ, Ascierto PA, Dummer R and Keilholz U: ESMO Guidelines Committee: Electronic address: simpleclinicalguidelines@esmo.org. Cutaneous melanoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up†. Ann Oncol. 30:1884–1901. 2019.PubMed/NCBI View Article : Google Scholar

Rosalia RA, Cruz LJ, van Duikeren S, Tromp AT, Silva AL, Jiskoot W, de Gruijl T, Löwik C, Oostendorp J, van der Burg SH and Ossendorp F: CD40-targeted dendritic cell delivery of PLGA-nanoparticle vaccines induce potent anti-tumor responses. Biomaterials. 40:88–97. 2015.PubMed/NCBI View Article : Google Scholar

Yuba E, Yamaguchi A, Yoshizaki Y, Harada A and Kono K: Bioactive polysaccharide-based pH-sensitive polymers for cytoplasmic delivery of antigen and activation of antigen-specific immunity. Biomaterials. 120:32–45. 2017.PubMed/NCBI View Article : Google Scholar

Buonaguro L, Tagliamonte M, Tornesello ML and Buonaguro FM: Developments in virus-like particle-based vaccines for infectious diseases and cancer. Expert Rev Vaccines. 10:1569–1583. 2011.PubMed/NCBI View Article : Google Scholar

Hassan HA, Smyth L, Wang JT, Costa PM, Ratnasothy K, Diebold SS, Lombardi G and Al-Jamal KT: Dual stimulation of antigen presenting cells using carbon nanotube-based vaccine delivery system for cancer immunotherapy. Biomaterials. 104:310–322. 2016.PubMed/NCBI View Article : Google Scholar

Wong HL, Rauth AM, Bendayan R, Manias JL, Ramaswamy M, Liu ZS, Erhan SZ and Wu XY: A new polymer-lipid hybrid nanoparticle system increases cytotoxicity of doxorubicin against multidrug-resistant human breast cancer cells. Pharm Res. 23:1574–1585. 2006.PubMed/NCBI View Article : Google Scholar

Waeckerle-Men Y and Groettrup M: PLGA microspheres for improved antigen delivery to dendritic cells as cellular vaccines. Adv Drug Deliv Rev. 57:475–482. 2005.PubMed/NCBI View Article : Google Scholar

Kim H, Niu L, Larson P, Kucaba TA, Murphy KA, James BR, Ferguson DM, Griffith TS and Panyam J: Polymeric nanoparticles encapsulating novel TLR7/8 agonists as immunostimulatory adjuvants for enhanced cancer immunotherapy. Biomaterials. 164:38–53. 2018.PubMed/NCBI View Article : Google Scholar

Heo MB and Lim YT: Programmed nanoparticles for combined immunomodulation, antigen presentation and tracking of immunotherapeutic cells. Biomaterials. 35:590–600. 2014.PubMed/NCBI View Article : Google Scholar

Kokate RA, Chaudhary P, Sun XL, Thamake SI, Maji S, Chib R, Vishwanatha JK and Jones HP: Rationalizing the use of functionalized poly-lactic-co-glycolic acid nanoparticles for dendritic cell-based targeted anticancer therapy. Nanomedicine (Lond). 11:479–494. 2016.PubMed/NCBI View Article : Google Scholar

Cruz LJ, Tacken PJ, Fokkink R, Joosten B, Stuart MC, Albericio F, Torensma R and Figdor CG: Targeted PLGA nano-but not microparticles specifically deliver antigen to human dendritic cells via DC-SIGN in vitro. J Control Release. 144:118–126. 2010.PubMed/NCBI View Article : Google Scholar

Nanjwade BK, Bechra HM, Derkar GK, Manvi FV and Nanjwade VK: Dendrimers: Emerging polymers for drug-delivery systems. Eur J Pharm Sci. 38:185–196. 2009.PubMed/NCBI View Article : Google Scholar

Torchilin VP: Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov. 4:145–160. 2005.PubMed/NCBI View Article : Google Scholar

Peng J, Xiao Y, Li W, Yang Q, Tan L, Jia Y, Qu Y and Qian Z: Photosensitizer micelles together with IDO inhibitor enhance cancer photothermal therapy and immunotherapy. Adv Sci (Weinh). 5(1700891)2018.PubMed/NCBI View Article : Google Scholar

Li H, Li Y, Wang X, Hou Y, Hong X, Gong T, Zhang Z and Sun X: Rational design of polymeric hybrid micelles to overcome lymphatic and intracellular delivery barriers in cancer immunotherapy. Theranostics. 7:4383–4398. 2017.PubMed/NCBI View Article : Google Scholar

Kong FY, Zhang JW, Li RF, Wang ZX, Wang WJ and Wang W: Unique roles of gold nanoparticles in drug delivery, targeting and imaging applications. Molecules. 22(1445)2017.PubMed/NCBI View Article : Google Scholar

Kodiha M, Wang YM, Hutter E, Maysinger D and Stochaj U: Off to the organelles-killing cancer cells with targeted gold nanoparticles. Theranostics. 5:357–370. 2015.PubMed/NCBI View Article : Google Scholar

Lin AY, Almeida JP, Bear A, Liu N, Luo L, Foster AE and Drezek RA: Gold nanoparticle delivery of modified CpG stimulates macrophages and inhibits tumor growth for enhanced immunotherapy. PLoS One. 8(e63550)2013.PubMed/NCBI View Article : Google Scholar

Dykman LA, Staroverov SA, Fomin AS, Khanadeev VA, Khlebtsov BN and Bogatyrev VA: Gold nanoparticles as an adjuvant: Influence of size, shape, and technique of combination with CpG on antibody production. Int Immunopharmacol. 54:163–168. 2018.PubMed/NCBI View Article : Google Scholar

Zhao Y, Zhao X, Cheng Y, Guo X and Yuan W: Iron oxide nanoparticles-based vaccine delivery for cancer treatment. Mol Pharm. 15:1791–1799. 2018.PubMed/NCBI View Article : Google Scholar

Slowing II, Vivero-Escoto JL, Wu CW and Lin VS: Mesoporous silica nanoparticles as controlled release drug delivery and gene transfection carriers. Adv Drug Deliv Rev. 60:1278–1288. 2008.PubMed/NCBI View Article : Google Scholar

Nguyen TL, Choi Y and Kim J: Mesoporous silica as a versatile platform for cancer immunotherapy. Adv Mater. 31(e1803953)2019.PubMed/NCBI View Article : Google Scholar

Croissant JG, Fatieiev Y and Khashab NM: Degradability and clearance of silicon, organosilica, silsesquioxane, silica mixed oxide, and mesoporous silica nanoparticles. Adv Mater 29, 2017.

Vallhov H, Gabrielsson S, Strømme M, Scheynius A and Garcia-Bennett AE: Mesoporous silica particles induce size dependent effects on human dendritic cells. Nano Lett. 7:3576–3582. 2007.PubMed/NCBI View Article : Google Scholar

Kwon D, Cha BG, Cho Y, Min J, Park EB, Kang SJ and Kim J: Extra-large pore mesoporous silica nanoparticles for directing in vivo M2 Macrophage polarization by delivering IL-4. Nano Lett. 17:2747–2756. 2017.PubMed/NCBI View Article : Google Scholar

Guo HC, Feng XM, Sun SQ, Wei YQ, Sun DH, Liu XT, Liu ZX, Luo JX and Yin H: Immunization of mice by hollow mesoporous silica nanoparticles as carriers of porcine circovirus type 2 ORF2 protein. Virol J. 9(108)2012.PubMed/NCBI View Article : Google Scholar

Wang C, Xu L, Liang C, Xiang J, Peng R and Liu Z: Immunological responses triggered by photothermal therapy with carbon nanotubes in combination with anti-CTLA-4 therapy to inhibit cancer metastasis. Adv Mater. 26:8154–8162. 2014.PubMed/NCBI View Article : Google Scholar

Raposo G, Nijman HW, Stoorvogel W, Liejendekker R, Harding CV, Melief CJ and Geuze HJ: B lymphocytes secrete antigen-presenting vesicles. J Exp Med. 183:1161–1172. 1996.PubMed/NCBI View Article : Google Scholar

Yang H, Fu H, Wang B, Zhang X, Mao J, Li X, Wang M, Sun Z, Qian H and Xu W: Exosomal miR-423-5p targets SUFU to promote cancer growth and metastasis and serves as a novel marker for gastric cancer. Mol Carcinog. 57:1223–1236. 2018.PubMed/NCBI View Article : Google Scholar

Lizotte PH, Wen AM, Sheen MR, Fields J, Rojanasopondist P, Steinmetz NF and Fiering S: In situ vaccination with cowpea mosaic virus nanoparticles suppresses metastatic cancer. Nat Nanotechnol. 11:295–303. 2016.PubMed/NCBI View Article : Google Scholar

Guo ZS, Liu Z and Bartlett DL: Oncolytic immunotherapy: Dying the right way is a key to eliciting potent antitumor immunity. Front Oncol. 4(74)2014.PubMed/NCBI View Article : Google Scholar

Fu LQ, Wang SB, Cai MH, Wang XJ, Chen JY, Tong XM, Chen XY and Mou XZ: Recent advances in oncolytic virus-based cancer therapy. Virus Res. 270(197675)2019.PubMed/NCBI View Article : Google Scholar

Round JL and Mazmanian SK: Inducible Foxp3⁺ regulatory T-cell development by a commensal bacterium of the intestinal microbiota. Proc Natl Acad Sci USA. 107:12204–12209. 2010.PubMed/NCBI View Article : Google Scholar

Cebula A, Seweryn M, Rempala GA, Pabla SS, McIndoe RA, Denning TL, Bry L, Kraj P, Kisielow P and Ignatowicz L: Thymus-derived regulatory T cells contribute to tolerance to commensal microbiota. Nature. 497:258–262. 2013.PubMed/NCBI View Article : Google Scholar

Ivanov II, Atarashi K, Manel N, Brodie EL, Shima T, Karaoz U, Wei D, Goldfarb KC, Santee CA, Lynch SV, et al: Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell. 139:485–498. 2009.PubMed/NCBI View Article : Google Scholar

Gaboriau-Routhiau V, Rakotobe S, Lécuyer E, Mulder I, Lan A, Bridonneau C, Rochet V, Pisi A, De Paepe M, Brandi G, et al: The key role of segmented filamentous bacteria in the coordinated maturation of gut helper T cell responses. Immunity. 31:677–689. 2009.PubMed/NCBI View Article : Google Scholar

Tomkovich S and Jobin C: Microbiota and host immune responses: A love-hate relationship. Immunology. 147:1–10. 2016.PubMed/NCBI View Article : Google Scholar

Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, Prieto PA, Vicente D, Hoffman K, Wei SC, et al: Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science. 359:97–103. 2018.PubMed/NCBI View Article : Google Scholar

Matson V, Fessler J, Bao R, Chongsuwat T, Zha Y, Alegre ML, Luke JJ and Gajewski TF: The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science. 359:104–108. 2018.PubMed/NCBI View Article : Google Scholar

Sivan A, Corrales L, Hubert N, Williams JB, Aquino-Michaels K, Earley ZM, Benyamin FW, Lei YM, Jabri B, Alegre ML, et al: Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science. 350:1084–1089. 2015.PubMed/NCBI View Article : Google Scholar

Matsumoto K, Yamamoto T, Kamata R and Maeda H: Pathogenesis of serratial infection: Activation of the Hageman factor-prekallikrein cascade by serratial protease. J Biochem. 96:739–749. 1984.PubMed/NCBI View Article : Google Scholar

Maeda H: Tumor-selective delivery of macromolecular drugs via the EPR effect: Background and future prospects. Bioconjug Chem. 21:797–802. 2010.PubMed/NCBI View Article : Google Scholar

Zhao M, Yang M, Li XM, Jiang P, Baranov E, Li S, Xu M, Penman S and Hoffman RM: Tumor-targeting bacterial therapy with amino acid auxotrophs of GFP-expressing Salmonella typhimurium. Proc Natl Acad Sci USA. 102:755–760. 2005.PubMed/NCBI View Article : Google Scholar

Marshall JS, Green AM, Pensky J, Williams S, Zinn A and Carlson DM: Measurement of circulating desialylated glycoproteins and correlation with hepatocellular damage. J Clin Invest. 54:555–562. 1974.PubMed/NCBI View Article : Google Scholar

Campbell RB, Fukumura D, Brown EB, Mazzola LM, Izumi Y, Jain RK, Torchilin VP and Munn LL: Cationic charge determines the distribution of liposomes between the vascular and extravascular compartments of tumors. Cancer Res. 62:6831–6836. 2002.PubMed/NCBI

Matsumura Y, Hamaguchi T, Ura T, Muro K, Yamada Y, Shimada Y, Shirao K, Okusaka T, Ueno H, Ikeda M and Watanabe N: Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin. Br J Cancer. 91:1775–1781. 2004.PubMed/NCBI View Article : Google Scholar

Park J, Choi Y, Chang H, Um W, Ryu JH and Kwon IC: Alliance with EPR effect: Combined strategies to improve the EPR effect in the tumor microenvironment. Theranostics. 9:8073–8090. 2019.PubMed/NCBI View Article : Google Scholar

Franqui LS, De Farias MA, Portugal RV, Costa CAR, Domingues RR, Souza Filho AG, Coluci VR, Leme AFP and Martinez DST: Interaction of graphene oxide with cell culture medium: Evaluating the fetal bovine serum protein corona formation towards in vitro nanotoxicity assessment and nanobiointeractions. Mater Sci Eng C Mater Biol Appl. 100:363–377. 2019.PubMed/NCBI View Article : Google Scholar

Glancy D, Zhang Y, Wu JLY, Ouyang B, Ohta S and Chan WCW: Characterizing the protein corona of sub-10 nm nanoparticles. J Control Release. 304:102–110. 2019.PubMed/NCBI View Article : Google Scholar

Lai W, Wang Q, Li L, Hu Z, Chen J and Fang Q: Interaction of gold and silver nanoparticles with human plasma: Analysis of protein corona reveals specific binding patterns. Colloids Surf B Biointerfaces. 152:317–325. 2017.PubMed/NCBI View Article : Google Scholar

Giulimondi F, Digiacomo L, Pozzi D, Palchetti S, Vulpis E, Capriotti AL, Chiozzi RZ, Laganà A, Amenitsch H, Masuelli L, et al: Interplay of protein corona and immune cells controls blood residency of liposomes. Nat Commun. 11(1697)2020.PubMed/NCBI View Article : Google Scholar

Partikel K, Korte R, Stein NC, Mulac D, Herrmann FC, Humpf HU and Langer K: Effect of nanoparticle size and PEGylation on the protein corona of PLGA nanoparticles. Eur J Pharm Biopharm. 141:70–80. 2019.PubMed/NCBI View Article : Google Scholar

Ekdahl KN, Fromell K, Mohlin C, Teramura Y and Nilsson B: A human whole-blood model to study the activation of innate immunity system triggered by nanoparticles as a demonstrator for toxicity. Sci Technol Adv Mater. 20:688–698. 2019.PubMed/NCBI View Article : Google Scholar

Gossmann R, Fahrländer E, Hummel M, Mulac D, Brockmeyer J and Langer K: Comparative examination of adsorption of serum proteins on HSA- and PLGA-based nanoparticles using SDS-PAGE and LC-MS. Eur J Pharm Biopharm. 93:80–87. 2015.PubMed/NCBI View Article : Google Scholar

Kah JC, Wong KY, Neoh KG, Song JH, Fu JW, Mhaisalkar S, Olivo M and Sheppard CJ: Critical parameters in the pegylation of gold nanoshells for biomedical applications: An in vitro macrophage study. J Drug Target. 17:181–193. 2009.PubMed/NCBI View Article : Google Scholar

Fleischer CC and Payne CK: Secondary structure of corona proteins determines the cell surface receptors used by nanoparticles. J Phys Chem B. 118:14017–14026. 2014.PubMed/NCBI View Article : Google Scholar

Mortimer GM, Butcher NJ, Musumeci AW, Deng ZJ, Martin DJ and Minchin RF: Cryptic epitopes of albumin determine mononuclear phagocyte system clearance of nanomaterials. ACS Nano. 8:3357–3366. 2014.PubMed/NCBI View Article : Google Scholar

Lartigue L, Wilhelm C, Servais J, Factor C, Dencausse A, Bacri JC, Luciani N and Gazeau F: Nanomagnetic sensing of blood plasma protein interactions with iron oxide nanoparticles: Impact on macrophage uptake. ACS Nano. 6:2665–2678. 2012.PubMed/NCBI View Article : Google Scholar

Barbero F, Russo L, Vitali M, Piella J, Salvo I, Borrajo ML, Busquets-Fité M, Grandori M, Bastús NG, Casals E and Puntes V: Formation of the protein corona: The interface between nanoparticles and the immune system. Semin Immunol. 34:52–60. 2017.PubMed/NCBI View Article : Google Scholar

Xu J, Wang H, Xu L, Chao Y, Wang C, Han X, Dong Z, Chang H, Peng R, Cheng Y and Liu Z: Nanovaccine based on a protein-delivering dendrimer for effective antigen cross-presentation and cancer immunotherapy. Biomaterials. 207:1–9. 2019.PubMed/NCBI View Article : Google Scholar

Li L, Goedegebuure SP and Gillanders WE: Preclinical and clinical development of neoantigen vaccines. Ann Oncol. 28 (Suppl 12):xii11–xii17. 2017.PubMed/NCBI View Article : Google Scholar

Gubin MM, Zhang X, Schuster H, Caron E, Ward JP, Noguchi T, Ivanova Y, Hundal J, Arthur CD, Krebber WJ, et al: Checkpoint blockade cancer immunotherapy targets tumour-specificmutant antigens. Nature. 515:577–581. 2014.PubMed/NCBI View Article : Google Scholar

Ott PA, Hu Z, Keskin DB, Shukla SA, Sun J, Bozym DJ, Zhang W, Luoma A, Giobbie-Hurder A, Peter L, et al: An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. 547:217–221. 2017.PubMed/NCBI View Article : Google Scholar

Sahin U, Derhovanessian E, Miller M, Kloke BP, Simon P, Löwer M, Bukur V, Tadmor AD, Luxemburger U, Schrörs B, et al: Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature. 547:222–226. 2017.PubMed/NCBI View Article : Google Scholar

Yadav M, Jhunjhunwala S, Phung QT, Lupardus P, Tanguay J, Bumbaca S, Franci C, Cheung TK, Fritsche J, Weinschenk T, et al: Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature. 515:572–576. 2014.PubMed/NCBI View Article : Google Scholar

Stone JD, Harris DT and Kranz DM: TCR affinity for p/MHC formed by tumor antigens that are self-proteins: Impact on efficacy and toxicity. Curr Opin Immunol. 33:16–22. 2015.PubMed/NCBI View Article : Google Scholar

Atif SM, Gibbings SL, Redente EF, Camp FA, Torres RM, Kedl RM, Henson PM and Claudia V: Immune surveillance by natural IgM is required for early neoantigen recognition and initiation of adaptive immunity. Am J Respir Cell Mol Biol. 59:580–591. 2018.PubMed/NCBI View Article : Google Scholar

Li Q, Zhang D, Zhang J, Jiang Y, Song A, Li Z and Luan Y: A three-in-one immunotherapy nanoweapon via cascade-amplifying cancer-immunity cycle against tumor metastasis, relapse, and postsurgical regrowth. Nano Lett. 19:6647–6657. 2019.PubMed/NCBI View Article : Google Scholar

Nonomura C, Otsuka M, Kondou R, Iizuka A, Miyata H, Ashizawa T, Sakura N, Yoshikawa S, Kiyohara Y, Ohshima K, et al: Identification of a neoantigen epitope in a melanoma patient with good response to anti-PD-1 antibody therapy. Immunol Lett. 208:52–59. 2019.PubMed/NCBI View Article : Google Scholar

Kreiter S, Selmi A, Diken M, Koslowski M, Britten CM, Huber C, Türeci O and Sahin U: Intranodal vaccination with naked antigen-encoding RNA elicits potent prophylactic and therapeutic antitumoral immunity. Cancer Res. 70:9031–9040. 2010.PubMed/NCBI View Article : Google Scholar

Hilf N, Kuttruff-Coqui S, Frenzel K, Bukur V, Stevanović S, Gouttefangeas C, Platten M, Tabatabai G, Dutoit V, van der Burg SH, et al: Actively personalized vaccination trial for newly diagnosed glioblastoma. Nature. 565:240–245. 2019.PubMed/NCBI View Article : Google Scholar

Sahin U, Oehm P, Derhovanessian E, Jabulowsky RA, Vormehr M, Gold M, Maurus D, Schwarck-Kokarakis D, Kuhn AN, Omokoko T, et al: An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma. Nature. 585:107–112. 2020.PubMed/NCBI View Article : Google Scholar

Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, Dudley ME, Wunderlich JR, Nahvi AV, Helman LJ, Mackall CL, et al: Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol. 29:917–924. 2011.PubMed/NCBI View Article : Google Scholar

Bencherif SA, Warren Sands R, Ali OA, Li WA, Lewin SA, Braschler TM, Shih TY, Verbeke CS, Bhatta D, Dranoff G and Mooney DJ: Injectable cryogel-based whole-cell cancer vaccines. Nat Commun. 6(7556)2015.PubMed/NCBI View Article : Google Scholar

Hassani Najafabadi A, Zhang J, Aikins ME, Najaf Abadi ZI, Liao F, Qin Y, Okeke EB, Scheetz LM, Nam J, Xu Y, et al: Cancer immunotherapy via targeting cancer stem cells using vaccine nanodiscs. Nano Lett. 20:7783–7792. 2020.PubMed/NCBI View Article : Google Scholar

Zheng F, Dang J, Zhang H, Xu F, Ba F, Zhang B, Cheng F, Chang AE, Wicha MS and Li Q: Cancer stem cell vaccination with PD-L1 and CTLA-4 blockades enhances the eradication of melanoma stem cells in a mouse tumor model. J Immunother. 41:361–368. 2018.PubMed/NCBI View Article : Google Scholar

Aggarwal S: Adverse effects of immuno-oncology drugs-Awareness, diagnosis, and management: A literature review of immune-mediated adverse events. Indian J Cancer. 56 (Suppl):S10–S22. 2019.PubMed/NCBI View Article : Google Scholar

Li Y, Fang M, Zhang J, Wang J, Song Y, Shi J, Li W, Wu G, Ren J, Wang Z, et al: Hydrogel dual delivered celecoxib and anti-PD-1 synergistically improve antitumor immunity. Oncoimmunology. 5(e1074374)2015.PubMed/NCBI View Article : Google Scholar

Wang C, Ye Y, Hochu GM, Sadeghifar H and Gu Z: Enhanced cancer immunotherapy by microneedle patch-assisted delivery of anti-PD1 antibody. Nano Lett. 16:2334–2340. 2016.PubMed/NCBI View Article : Google Scholar

Ordikhani F, Uehara M, Kasinath V, Dai L, Eskandari SK, Bahmani B, Yonar M, Azzi JR, Haik Y, Sage PT, et al: Targeting antigen-presenting cells by anti-PD-1 nanoparticles augments antitumor immunity. JCI Insight. 3(e122700)2018.PubMed/NCBI View Article : Google Scholar

Li SY, Liu Y, Xu CF, Shen S, Sun R, Du XJ, Xia JX, Zhu YH and Wang J: Restoring anti-tumor functions of T cells via nanoparticle-mediated immune checkpoint modulation. J Control Release. 231:17–28. 2016.PubMed/NCBI View Article : Google Scholar

Alimohammadi R, Alibeigi R, Nikpoor AR, Chalbatani GM, Webster TJ, Jaafari MR and Jalali SA: Encapsulated checkpoint blocker before chemotherapy: The optimal sequence of anti-CTLA-4 and doxil combination therapy. Int J Nanomedicine. 15:5279–5288. 2020.PubMed/NCBI View Article : Google Scholar

Zhang YX, Zhao YY, Shen J, Sun X, Liu Y, Liu H and Wang Y and Wang Y: Nanoenabled modulation of acidic tumor microenvironment reverses anergy of infiltrating T cells and potentiates anti-PD-1 therapy. Nano Lett. 19:2774–2783. 2019.PubMed/NCBI View Article : Google Scholar

Hei Y, Teng B, Zeng Z, Zhang S, Li Q, Pan J, Luo Z, Xiong C and Wei S: Multifunctional immunoliposomes combining catalase and PD-L1 antibodies overcome tumor hypoxia and enhance immunotherapeutic effects against melanoma. Int J Nanomedicine. 15:1677–1691. 2020.PubMed/NCBI View Article : Google Scholar

Mishchenko T, Mitroshina E, Balalaeva I, Krysko O, Vedunova M and Krysko DV: An emerging role for nanomaterials in increasing immunogenicity of cancer cell death. Biochim Biophys Acta Rev Cancer. 1871:99–108. 2019.PubMed/NCBI View Article : Google Scholar

Obeid M, Panaretakis T, Joza N, Tufi R, Tesniere A, van Endert P, Zitvogel L and Kroemer G: Calreticulin exposure is required for the immunogenicity of gamma-irradiation and UVC light-induced apoptosis. Cell Death Differ. 14:1848–1850. 2007.PubMed/NCBI View Article : Google Scholar

Garg AD, Martin S, Golab J and Agostinis P: Danger signalling during cancer cell death: Origins, plasticity and regulation. Cell Death Differ. 21:26–38. 2014.PubMed/NCBI View Article : Google Scholar

Min Y, Roche KC, Tian S, Eblan MJ, McKinnon KP, Caster JM, Chai S, Herring LE, Zhang L, Zhang T, et al: Antigen-capturing nanoparticles improve the abscopal effect and cancer immunotherapy. Nat Nanotechnol. 12:877–882. 2017.PubMed/NCBI View Article : Google Scholar

Seth A, Heo MB and Lim YT: Poly (γ-glutamic acid) based combination of water-insoluble paclitaxel and TLR7 agonist for chemo-immunotherapy. Biomaterials. 35:7992–8001. 2014.PubMed/NCBI View Article : Google Scholar

Deng H, Tan S, Gao X, Zou C, Xu C, Tu K, Song Q, Fan F, Huang W and Zhang Z: Cdk5 knocking out mediated by CRISPR-Cas9 genome editing for PD-L1 attenuation and enhanced antitumor immunity. Acta Pharm Sin B. 10:358–373. 2020.PubMed/NCBI View Article : Google Scholar

Tzeng SY, Patel KK, Wilson DR, Meyer RA, Rhodes KR and Green JJ: In situ genetic engineering of tumors for long-lasting and systemic immunotherapy. Proc Natl Acad Sci USA. 117:4043–4052. 2020.PubMed/NCBI View Article : Google Scholar

Guan X, Lin L, Chen J, Hu Y, Sun P, Tian H, Maruyama A and Chen X: Efficient PD-L1 gene silence promoted by hyaluronidase for cancer immunotherapy. J Control Release. 293:104–112. 2019.PubMed/NCBI View Article : Google Scholar

Hamdy S, Molavi O, Ma Z, Haddadi A, Alshamsan A, Gobti Z, Elhasi S, Samuel J and Lavasanifar A: Co-delivery of cancer-associated antigen and Toll-like receptor 4 ligand in PLGA nanoparticles induces potent CD8⁺ T cell-mediated anti-tumor immunity. Vaccine. 26:5046–5057. 2008.PubMed/NCBI View Article : Google Scholar

Zhang Z, Tongchusak S, Mizukami Y, Kang YJ, Ioji T, Touma M, Reinhold B, Keskin DB, Reinherz EL and Sasada T: Induction of anti-tumor cytotoxic T cell responses through PLGA-nanoparticle mediated antigen delivery. Biomaterials. 32:3666–3678. 2011.PubMed/NCBI View Article : Google Scholar

Peranzoni E, Lemoine J, Vimeux L, Feuillet V, Barrin S, Kantari-Mimoun C, Bercovici N, Guérin M, Biton J, Ouakrim H, et al: Macrophages impede CD8 T cells from reaching tumor cells and limit the efficacy of anti-PD-1 treatment. Proc Natl Acad Sci USA. 115:E4041–E4050. 2018.PubMed/NCBI View Article : Google Scholar

Prendergast GC, Malachowski WP, DuHadaway JB and Muller AJ: Discovery of IDO1 inhibitors: From bench to bedside. Cancer Res. 77:6795–6811. 2017.PubMed/NCBI View Article : Google Scholar

Rodell CB, Arlauckas SP, Cuccarese MF, Garris CS, Li R, Ahmed MS, Kohler RH, Pittet MJ and Weissleder R: TLR7/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy. Nat Biomed Eng. 2:578–588. 2018.PubMed/NCBI View Article : Google Scholar

Chen Q, Wang C, Zhang X, Chen G, Hu Q, Li H, Wang J, Wen D, Zhang Y, Lu Y, et al: In situ sprayed bioresponsive immunotherapeutic gel for post-surgical cancer treatment. Nat Nanotechnol. 14:89–97. 2019.PubMed/NCBI View Article : Google Scholar

Alupei MC, Licarete E, Patras L and Banciu M: Liposomal simvastatin inhibits tumor growth via targeting tumor-associated macrophages-mediated oxidative stress. Cancer Lett. 356:946–952. 2015.PubMed/NCBI View Article : Google Scholar

Qian Y, Qiao S, Dai Y, Xu G, Dai B, Lu L, Yu X, Luo Q and Zhang Z: Molecular-targeted immunotherapeutic strategy for melanoma via dual-targeting nanoparticles delivering small interfering RNA to tumor-associated macrophages. ACS Nano. 11:9536–9549. 2017.PubMed/NCBI View Article : Google Scholar

Hornyák L, Dobos N, Koncz G, Karányi Z, Páll D, Szabó Z, Halmos G and Székvölgyi L: The role of indoleamine-2,3-dioxygenase in cancer development, diagnostics, and therapy. Front Immunol. 9(151)2018.PubMed/NCBI View Article : Google Scholar

Orabona C, Pallotta MT, Volpi C, Fallarino F, Vacca C, Bianchi R, Belladonna ML, Fioretti MC, Grohmann U and Puccetti P: SOCS3 drives proteasomal degradation of indoleamine 2,3-dioxygenase (IDO) and antagonizes IDO-dependent tolerogenesis. Proc Natl Acad Sci USA. 105:20828–20833. 2008.PubMed/NCBI View Article : Google Scholar

Shou D, Liang W, Song Z, Yin J, Sun Q and Gong W: Suppressive role of myeloid-derived suppressor cells (MDSCs) in the microenvironment of breast cancer and targeted immunotherapies. Oncotarget. 7:64505–64511. 2016.PubMed/NCBI View Article : Google Scholar

Zhao Q, Kuang DM, Wu Y, Xiao X, Li XF, Li TJ and Zheng L: Activated CD69⁺ T cells foster immune privilege by regulating IDO expression in tumor-associated macrophages. J Immunol. 188:1117–1124. 2012.PubMed/NCBI View Article : Google Scholar

Cheng K, Ding Y, Zhao Y, Ye S, Zhao X, Zhang Y, Ji T, Wu H, Wang B, Anderson GJ, et al: Sequentially responsive therapeutic peptide assembling nanoparticles for dual-targeted cancer immunotherapy. Nano Lett. 18:3250–3258. 2018.PubMed/NCBI View Article : Google Scholar

Ye Y, Wang J, Hu Q, Hochu GM, Xin H, Wang C and Gu Z: Synergistic transcutaneous immunotherapy enhances antitumor immune responses through delivery of checkpoint inhibitors. ACS Nano. 10:8956–8963. 2016.PubMed/NCBI View Article : Google Scholar

Aoki CA, Borchers AT, Li M, Flavell RA, Bowlus CL, Ansari AA and Gershwin ME: Transforming growth factor beta (TGF-beta) and autoimmunity. Autoimmun Rev. 4:450–459. 2005.PubMed/NCBI View Article : Google Scholar

Zheng Y, Tang L, Mabardi L, Kumari S and Irvine DJ: Enhancing adoptive cell therapy of cancer through targeted delivery of small-molecule immunomodulators to internalizing or noninternalizing receptors. ACS Nano. 11:3089–3100. 2017.PubMed/NCBI View Article : Google Scholar

Kang M, Hong J, Jung M, Kwon SP, Song SY, Kim HY, Lee JR, Kang S, Han J, Koo JH, et al: T-cell-mimicking nanoparticles for cancer immunotherapy. Adv Mater. 32(e2003368)2020.PubMed/NCBI View Article : Google Scholar

Shi Y and Lammers T: Combining nanomedicine and immunotherapy. Acc Chem Res. 52:1543–1554. 2019.PubMed/NCBI View Article : Google Scholar

Xu Z, Wang Y, Zhang L and Huang L: Nanoparticle-delivered transforming growth factor-β siRNA enhances vaccination against advanced melanoma by modifying tumor microenvironment. ACS Nano. 8:3636–3645. 2014.PubMed/NCBI View Article : Google Scholar

Kohlhapp FJ and Kaufman HL: Molecular pathways: Mechanism of action for talimogene laherparepvec, a new oncolytic virus immunotherapy. Clin Cancer Res. 22:1048–1054. 2016.PubMed/NCBI View Article : Google Scholar

Ott PA and Hodi FS: Talimogene laherparepvec for the treatment of advanced melanoma. Clin Cancer Res. 22:3127–3131. 2016.PubMed/NCBI View Article : Google Scholar

Conry RM, Westbrook B, McKee S and Norwood TG: Talimogene laherparepvec: First in class oncolytic virotherapy. Hum Vaccin Immunother. 14:839–846. 2018.PubMed/NCBI View Article : Google Scholar

Andtbacka RHI, Collichio F, Harrington KJ, Middleton MR, Downey G, Ӧhrling K and Kaufman HL: Final analyses of OPTiM: A randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III-IV melanoma. J Immunother Cancer. 7(145)2019.PubMed/NCBI View Article : Google Scholar

Long GV, Dummer R, Ribas A, Puzanov I, Michielin O, Vanderwalde AM, Andtbacka RHI, Cebon J, Fernandez E, Malvehy J, et al: A phase I/III, multicenter, open-label trial of talimogene laherparepvec (T-VEC) in combination with pembrolizumab for the treatment of unresected, stage IIIb-IV melanoma (MASTERKEY-265). J Immunother Cancer. 3 (Suppl 2)(P181)2015.

Puzanov I, Milhem MM, Minor D, Hamid O, Li A, Chen L, Chastain M, Gorski KS, Anderson A, Chou J, et al: Talimogene laherparepvec in combination with ipilimumab in previously untreated, unresectable stage IIIB-IV melanoma. J Clin Oncol. 34:2619–2626. 2016.PubMed/NCBI View Article : Google Scholar

Chesney J, Puzanov I, Collichio F, Singh P, Milhem MM, Glaspy J, Hamid O, Ross M, Friedlander P, Garbe C, et al: Randomized, open-label phase II study evaluating the efficacy and safety of talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone in patients with advanced, unresectable melanoma. J Clin Oncol. 36:1658–1667. 2018.PubMed/NCBI View Article : Google Scholar

Dummer R, Gyorki DE, Hyngstrom JR, Berger AC, Conry RM, Demidov LV, Sharma A, Treichel S, Faries MB and Ross MI: One-year (yr) recurrence-free survival (RFS) from a randomized, open label phase II study of neoadjuvant (neo) talimogene laherparepvec (T-VEC) plus surgery (surgx) versus surgx for resectable stage IIIB-IVM1a melanoma (MEL). J Clin Oncol. 37 (Suppl 15)(S9520)2019.

Trager MH, Geskin LJ and Saenger YM: Oncolytic viruses for the treatment of metastatic melanoma. Curr Treat Options Oncol. 21(26)2020.PubMed/NCBI View Article : Google Scholar

Ancuceanu R, Dinu M, Neaga I, Laszlo FG and Boda D: Development of QSAR machine learning-based models to forecast the effect of substances on malignant melanoma cells. Oncol Lett. 17:4188–4196. 2019.PubMed/NCBI View Article : Google Scholar

Ion A, Popa IM, Papagheorghe LML, Lisievici C, Lupu M, Voiculescu V, Caruntu C and Boda D: Proteomic approaches to biomarker discovery in cutaneous T-cell lymphoma. Dis Markers. 2016(9602472)2016.PubMed/NCBI View Article : Google Scholar

Boda D, Negrei C, Arsene AL, Caruntu C, Lupuleasa D and Ion RM: Spectral and photochemical properties of hyperbranched nanostructures based on gardiquimod and TPPS4. Farmacia. 63:218–223. 2015.

Boda D: Cellomics as integrative omics for cancer. Curr Proteomics. 10:237–245. 2013.

Lupu M, Caruntu A, Caruntu C, Papagheorghe LML, Ilie MA, Voiculescu V, Boda D, Constantin C, Tanase C, Sifaki M, et al: Neuroendocrine factors: The missing link in non-melanoma skin cancer (Review). Oncol Rep. 38:1327–1340. 2017.PubMed/NCBI View Article : Google Scholar

Zurac S, Neagu M, Constantin C, Cioplea M, Nedelcu R, Bastian A, Popp C, Nichita L, Andrei R, Tebeica T, et al: Variations in the expression of TIMP1, TIMP2 and TIMP3 in cutaneous melanoma with regression and their possible function as prognostic predictors. Oncol Lett. 11:3354–3360. 2016.PubMed/NCBI View Article : Google Scholar